Pulmatrix Inc. (PULM) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for PULM, including 8 SEC filings and 2 press releases and news items. The most recent was published Oct 30, 2026.
Financial highlights
Full financials- Net income, TTM
- -$4.01M
- Cash
- $2.17M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks31-20%
2026-05-102026-11-01
Mix2390d
- SEC Filings19(83%)
- Dividends2(9%)
- Other2(9%)
Latest news
25 items- PREos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat StudyInterim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos’s R&D Facility; Data Support IND-Enabling Development Ahead of Planned First-in-Human Trials HOUSTON, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. ("Eos" or the "Company"), a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today announced early interim results from a study of its lead MitoXcel™ geropeptide, PTC-2105, in aged rats, conducted at the BIO-VITAL Program Preclinical Testing Core facility of the Albert Einstein College of Medicine ("Einstein") in the Bronx, New Yor
- SECSEC Form 425 filed by Pulmatrix Inc.425 - Pulmatrix, Inc. (0001574235) (Subject)
- SECSEC Form 8-K filed by Pulmatrix Inc.8-K - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form 424B3 filed by Pulmatrix Inc.424B3 - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form EFFECT filed by Pulmatrix Inc.EFFECT - Pulmatrix, Inc. (0001574235) (Filer)
- PREos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived MouseIn naturally aged mice treated from 80 weeks of age and followed until natural death, once-weekly PTC-2105 (25 mg/kg) significantly increased overall survival versus saline (log-rank p = 0.0142)"Speedy," a PTC-2105-treated mouse now more than 167 weeks old, has outlived every saline-treated negative control in his study by more than 20% and remains active day and nightNew "Team Speedy" webpage, launching today at eossenolytix.com/team-speedy, invites the public to watch Speedy, predict how far he will go, and sign up for milestone alerts BERLIN and HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. ("Eos" or the "Company") a biotechnology company developing mitochondr
- SECSEC Form 425 filed by Pulmatrix Inc.425 - Pulmatrix, Inc. (0001574235) (Subject)
- SECSEC Form 425 filed by Pulmatrix Inc.425 - Pulmatrix, Inc. (0001574235) (Subject)
- SECSEC Form 424B3 filed by Pulmatrix Inc.424B3 - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form DEFA14A filed by Pulmatrix Inc.DEFA14A - Pulmatrix, Inc. (0001574235) (Filer)
- SECAmendment: SEC Form S-3/A filed by Pulmatrix Inc.S-3/A - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form EFFECT filed by Pulmatrix Inc.EFFECT - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form 424B3 filed by Pulmatrix Inc.424B3 - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form DEFM14A filed by Pulmatrix Inc.DEFM14A - Pulmatrix, Inc. (0001574235) (Filer)
- SECAmendment: SEC Form S-4/A filed by Pulmatrix Inc.S-4/A - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form 425 filed by Pulmatrix Inc.425 - Pulmatrix, Inc. (0001574235) (Subject)
- PREos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting MitochondriaFounder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicineEos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesityEos anticipates closing of Pulmatrix, Inc. merger in Q4 subject to customary closing conditions HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. ("Eos" or the "Company"), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and metabolic health by targeting the underlying biological mechanisms of aging, today announced that it will present
- SECAmendment: SEC Form S-4/A filed by Pulmatrix Inc.S-4/A - Pulmatrix, Inc. (0001574235) (Filer)
- SECAmendment: SEC Form S-4/A filed by Pulmatrix Inc.S-4/A - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form 10-Q filed by Pulmatrix Inc.10-Q - Pulmatrix, Inc. (0001574235) (Filer)
- SECPulmatrix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pulmatrix, Inc. (0001574235) (Filer)
- PRPulmatrix Announces Second Quarter 2026 Financial Results and Progress on MergerForm S-4 filed related to the announced merger agreement with Eos SENOLYTIXFRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced its second quarter financial results for 2026 and provided a corporate update related to the merger agreement with Eos SENOLYTIX announced at the end of the first quarter of 2026. Peter Ludlum
- SECAmendment: SEC Form S-3/A filed by Pulmatrix Inc.S-3/A - Pulmatrix, Inc. (0001574235) (Filer)
- SECAmendment: SEC Form S-4/A filed by Pulmatrix Inc.S-4/A - Pulmatrix, Inc. (0001574235) (Filer)
- SECSEC Form S-4 filed by Pulmatrix Inc.S-4 - Pulmatrix, Inc. (0001574235) (Filer)
PULM FAQ
9 questionsWhat does Pulmatrix Inc. do?
Pulmatrix, Inc., a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal...What is the latest news on PULM?
In the last 30 days Quantisnow tracked 10 wire items for PULM: 8 SEC filings and 2 press releases and news items. The most recent was published on October 30, 2026.Is PULM profitable?
No. Pulmatrix Inc. reported a net loss of $4.01M for the twelve months ended Jun 30, 2026.How much cash and debt does PULM have?
Pulmatrix Inc. reported $2.17M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does PULM stock trade?
Pulmatrix Inc. (PULM) is listed on NASDAQ.What sector and industry is PULM in?
Pulmatrix Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pulmatrix Inc. go public?
Pulmatrix Inc. (PULM) completed its IPO in 2014.What companies are similar to PULM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PULM side-by-side with any of them on Quantisnow.How can I track PULM on Quantisnow?
Quantisnow aggregates Pulmatrix Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PULM to receive live email and push alerts on every new disclosure.